rTGFβ treatment could downregulate TβRII and upregulate TβRI expressions in ccRCC, which is probably consistent with the link between enhanced tumor growth and TβRII deficiency [295]. The gene discussed is TGFBR2; the disease is nonpapillary renal cell carcinoma.